Cell therapy procedure using anti‐inflammatory macrophage M2 can potentially reduce Clinical Score in animals with Experimental Autoimmune Encephalomyelitis: A preclinical systematic review and meta‐analysis study

Abstract

Macrophage M2 (MP2)‐based cell therapy is a novel medicinal treatment for animals with Experimental Autoimmune Encephalomyelitis (EAE) as an experimental model of multiple sclerosis (MS). This systematic review and meta‐analysis study was designed to assess the overall therapeutic effects of MP2 cell therapy on Clinical Score and motor impairment in EAE‐induced animals. All experiments on MP2 cell therapy in animals with EAE were gathered (by October 2, 2022) from English (PubMed, Scopus, WoS, Science Direct, and ISC) and Persian (MagIran and SID) databases. The searching strategy was designed using “Experimental Autoimmune Encephalomyelitis,” “Multiple Sclerosis,” and “Macrophage M2” keywords. Following primary and secondary screenings, eligible papers were selected based on the PRISMA 2020 guideline, and the study quality was assessed using the Animal Research: Reporting of In Vivo Experiments (ARRIVE) checklist. The difference in means of Clinical Score (score 0–5) as the effect size (ES) was analyzed based on the random effect model (CMA software, v.2). Subgrouping (EAE phases of Onset, Peak, and Recovery) was applied, and I2 index was used to assess the heterogeneity index. Publication bias and sensitivity indices were also evaluated. P < 0.05 was considered significant, and the confidence interval (CI) was determined 95%. Among 22 gathered papers, medium to high quality studies were selected for meta‐analysis. Difference in means, P value, and I2 for Onset, Peak, and Recovery phases were 0.082 (CI95%: −0.323–0.159, P value: 0.504, I2: 67.961%), −0.606 (CI95%: −1.518 to −0.305, P value: 0.192, I2: 96.070%), and −1.103 (CI95%: −1.390 to −0.816, P value: 0.000, I2: 30.880%), respectively and Overall Effect was found −0.509 (CI95%: −0.689 to −0.328, P value < 0.001). Also, P value (two‐tailed) indices for publication bias were 0.366 and 0.583 for Egger's regression intercept and Begg rank correlation, respectively. The P value for sensitivity was detected 0.003. Cell therapy procedure using MP2 can potentially alleviate the Clinical Scores Index and correct the motor defects in Recovery phase of EAE animals. In healthy mice, the brain and myelin surrounding neurons are in a healthy and physiological state (1). To evaluate MS in humans, it is necessary to model this type of disease in animals using EAE procedure through subcutaneous injection of CFA, MOG35–55, MT, and Pert. Thus, inflammation and autoimmunity occur, which finally lead to myelin destruction and motor symptoms (2). By aspiration of progenitor cells available in bone marrow, the MP2 can be isolated and cultured. By activation of these types of cells, a rich collection of MP2 can be prepared for the cell‐therapy process (3). After injection through the tail vein or intra‐peritoneal procedure, these cells can be located in CNS through crossing from the BBB. They begin their anti‐inflammatory activities and help repair the damaged myelin (4). Eventually, the clinical symptoms can be modified considerably, and the animal motor function improve...

Intraperitoneal injection of mesenchymal stem cells-conditioned media (MSCS-CM) treated monocyte can potentially alleviate motor defects in experimental autoimmune encephalomyelitis female mice; an original experimental study

“…While more research is needed to fully understand the mechanisms underlying cell therapy for MS treatment, it holds great potential as a novel therapeutic approach for this debilitating disease. MPM2 is a type of immune cell which possesses unique cellular features and anti-in ammatory characteristics (9). These cells are known to play a crucial role in regulation of the immune response and promotion of tissue repair.…”